Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cybin Inc N.CYBN

Alternate Symbol(s):  CYBN

Healthcare Drug Manufacturers - Specialty & Generic
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary... see more

Recent & Breaking News (NEO:CYBN)

Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry

Business Wire 1 day ago

Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder

Business Wire 3 days ago

Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Business Wire 9 days ago

Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million

Business Wire March 19, 2024

Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas

Business Wire March 18, 2024

Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

Business Wire March 15, 2024

Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Business Wire March 14, 2024

Announces Oversubscribed Private Placement of U.S. $150 Million

Business Wire March 13, 2024

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Business Wire March 13, 2024

Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003

Business Wire March 12, 2024

Cybin to Present at the TD Cowen 44th Annual Health Care Conference

Business Wire February 27, 2024

Cybin Reports Third Quarter Financial Results and Recent Business Highlights

Business Wire February 14, 2024

Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program

Business Wire February 7, 2024

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Business Wire January 23, 2024

Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Business Wire January 8, 2024

Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs

Business Wire January 4, 2024

Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program

Business Wire December 6, 2023

Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results

Business Wire December 5, 2023

Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Business Wire November 30, 2023

Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City

Business Wire November 20, 2023